Fertigyn HP: Precision hCG Formulation for Advanced Hormone Therapy
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $24.37 | $73.10 (0%) | 🛒 Add to cart |
| 5 | $22.36
Best per ampoule | $121.83 $111.80 (8%) | 🛒 Add to cart |
| Product dosage: 2000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $14.33 | $43.00 (0%) | 🛒 Add to cart |
| 5 | $12.90
Best per ampoule | $71.67 $64.50 (10%) | 🛒 Add to cart |
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $15.77 | $47.30 (0%) | 🛒 Add to cart |
| 5 | $14.62
Best per ampoule | $78.83 $73.10 (7%) | 🛒 Add to cart |
Fertigyn HP (Human Chorionic Gonadotropin) represents a significant advancement in hormone therapy formulations, specifically engineered for medical professionals requiring exact dosing control and reliable biological activity. This highly purified urinary-derived hCG preparation maintains exceptional biological potency (approximately 6,000 IU per vial) while ensuring minimal impurities and batch-to-batch consistency. Developed for specialized therapeutic applications, Fertigyn HP offers clinicians a trusted option for managing complex endocrine conditions, fertility challenges, and specific metabolic disorders. Its lyophilized formulation allows for precise reconstitution and dosing flexibility, making it particularly valuable in protocols requiring meticulous hormone modulation.
Features
- Highly purified human chorionic gonadotropin (hCG) derived from human urine
- Lyophilized powder formulation in sterile vials containing approximately 6,000 IU
- Biological activity standardized against WHO International Standard
- Low impurity profile with minimal cross-reactivity to other glycoprotein hormones
- Precise dosing capability with multiple reconstitution volume options
- Temperature-stable lyophilized form with extended shelf life
- Manufactured under strict GMP conditions with comprehensive quality control
- Rubber-stoppered vials with aluminum seals for maintained sterility
- Consistent batch-to-batch potency within ±5% variation
- Compatibility with standard bacteriostatic water for injection
Benefits
- Enables precise hormonal stimulation for controlled ovarian hyperstimulation in assisted reproduction
- Supports complete spermatogenesis in hypogonadotropic hypogonadism when combined with FSH
- Facilitates testicular descent in cryptorchidism when anatomical obstruction is absent
- Provides reliable luteal phase support in fertility treatment cycles
- Allows for customized dosing in weight management protocols under specialist supervision
- Offers predictable pharmacokinetic profile for timing-critical therapeutic applications
Common use
Fertigyn HP is primarily employed in reproductive medicine and endocrine disorders. In female patients, it is utilized for final follicular maturation triggering in controlled ovarian stimulation cycles, typically following gonadotropin preparation. For male patients, it serves as replacement therapy for LH deficiency in hypogonadotropic hypogonadism, stimulating testosterone production and spermatogenesis when combined with FSH. Additional applications include treatment of prepubertal cryptorchidism not due to anatomical obstruction and off-label use in specialized weight management protocols where hCG’s metabolic effects are utilized under rigorous medical supervision.
Dosage and direction
Reconstitute with 1-5 mL of bacteriostatic water for injection, depending on desired concentration. Gently swirl until completely dissolved—do not shake vigorously. Administer by subcutaneous or intramuscular injection using aseptic technique.
Female infertility: 5,000-10,000 IU as single dose for final follicular maturation, timed according to follicular development monitoring.
Male hypogonadotropic hypogonadism: 1,000-4,000 IU 2-3 times weekly, adjusted based on testosterone response and spermatogenesis parameters.
Prepubertal cryptorchidism: 500-1,000 IU 2-3 times weekly for up to 8 weeks, with surgical evaluation if no response.
Dosing must be individualized based on patient response, laboratory parameters, and treatment objectives. Always follow specific protocol guidelines for the indicated condition.
Precautions
- Strict adherence to aseptic technique during reconstitution and administration is mandatory
- Regular monitoring of ovarian size and estradiol levels required in fertility treatments to prevent OHSS
- Testosterone levels should be monitored in male patients to avoid supraphysiological levels
- Use with caution in patients with history of epilepsy, migraine, asthma, or cardiac or renal dysfunction
- May influence thyroid function tests due to structural similarity to TSH
- Patients with obesity may require dose adjustment due to altered pharmacokinetics
- Not recommended for use in patients with hormone-dependent malignancies
- Educate patients on proper injection technique and rotation of injection sites
Contraindications
- Prior hypersensitivity to hCG or any component of the formulation
- Precocious puberty
- Prostatic carcinoma or other androgen-dependent neoplasms
- Uncontrolled thyroid or adrenal dysfunction
- Organic intracranial lesions such as pituitary tumors
- Ovarian cyst or enlargement not due to polycystic ovarian syndrome
- Abnormal uterine bleeding of undetermined etiology
- Pregnancy (except in specific fertility treatment protocols under specialist care)
- Active thromboembolic disorders
Possible side effect
Common (≥1/100): Injection site reactions (pain, redness, swelling), headache, irritability, restlessness, fatigue, edema
Uncommon (≥1/1000): Gynecomastia in males, ovarian hyperstimulation syndrome (OHSS), nausea, vomiting, depression, fever, rash, precocious puberty in children
Rare (<1/1000): Arterial thromboembolism, allergic reactions including anaphylaxis, hydrothorax, ascites, hemoperitoneum, ovarian torsion, multiple pregnancy
Patients should be advised to report severe abdominal pain, shortness of breath, chest pain, or severe headache immediately.
Drug interaction
- May enhance effects of corticosteroids
- Concomitant use with gonadotropins may increase risk of OHSS
- Androgens may potentiate adverse effects such as edema and acne
- Drugs affecting pituitary-gonadal axis (e.g., GnRH analogs) may alter response
- Anticonvulsants and antibiotics may reduce efficacy due to increased metabolism
- Oral estrogens may interfere with response in fertility treatments
- Always review complete medication list before initiation
Missed dose
If a dose is missed, administer as soon as remembered unless it is close to the next scheduled dose. Do not double the dose to make up for a missed administration. For fertility treatment cycles involving precise timing, contact the treating physician immediately for guidance, as timing adjustments may be necessary. Maintain regular dosing schedule thereafter.
Overdose
Symptoms may include severe OHSS (rapid weight gain, abdominal pain, nausea, vomiting, decreased urine output), gynecomastia, and emotional lability. In case of suspected overdose, discontinue treatment immediately and provide supportive care. OHSS may require hospitalization for management including fluid balance monitoring, analgesics, and in severe cases, paracentesis. There is no specific antidote; treatment should be symptomatic and supportive.
Storage
Store unopened vials at 2-8°C (36-46°F). Protect from light. Do not freeze. After reconstitution, store at 2-8°C and use within 30 days. Discard any solution that appears cloudy or contains particulate matter. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals only. Fertigyn HP is a prescription medication that must be used under appropriate medical supervision. The prescribing physician should be thoroughly familiar with the product characteristics, indications, and contraindications. Treatment should be tailored to individual patient needs with appropriate monitoring. This document does not replace official prescribing information or professional medical judgment.
Reviews
“The batch consistency and reliable biological activity make Fertigyn HP my preferred choice for ovarian stimulation protocols. The precise dosing capability allows for fine-tuning based on individual patient response.” - Reproductive Endocrinologist, 15 years experience
“In my practice treating hypogonadotropic hypogonadism, Fertigyn HP has demonstrated predictable testosterone response and excellent tolerability profile. The lyophilized formulation maintains stability throughout the treatment course.” - Andrology Specialist
“The low impurity profile reduces the risk of antibody formation in long-term therapy, which is crucial for patients requiring extended treatment duration.” - Clinical Pharmacologist
“While effective, requires careful patient selection and monitoring—particularly for ovarian hyperstimulation risk in fertility patients. When used appropriately, outcomes are excellent.” - IVF Program Director